JAK2 and hepatocellular carcinoma: Notably, it has been found that the drug oxysophocarpine decreases FGL1 expression by downregulating IL-6-mediated JAK2/STAT3 signaling, ultimately enhancing the immunotherapeutic effect of CD8+ T cells against HCC in vivo and in vitro [31].